|
Cardiomyopathy, Dilated
|
0.010 |
Biomarker
|
group |
BEFREE |
Here, we report that myocardial-specific deletion of <i>Jarid2</i> using α<i>MHC</i>::<i>Cre</i> mice (<i>Jarid2</i><sup>αMHC</sup>) causes dilated cardiomyopathy (DCM) and premature death 6-9 months after birth.
|
30700554 |
2019 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl.
|
30783079 |
2019 |
|
Carcinogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Downregulation of Jarid2 with shRNA transfection obviously inhibited the proliferation, migration and tumorigenesis of bladder cancer T24 and HT-1376 cells and induced cell apoptosis.
|
31125562 |
2019 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl.
|
30783079 |
2019 |
|
Cardiomyopathy, Familial Idiopathic
|
0.010 |
Biomarker
|
disease |
BEFREE |
To determine functions of Jarid2 in the adult heart and DCM, we analyzed gene expression in the heart at postnatal day (p)10 (neonatal) and 7 months (DCM).
|
30700554 |
2019 |
|
secondary acute myeloid leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic deletion of Jarid2 either reduced overall survival of animals with MPNs or drove transformation to sAML, depending on the timing and context of co-operating mutations.
|
30423295 |
2018 |
|
Hematopoietic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
These studies establish JARID2 as a bona fide hematopoietic tumor suppressor and highlight potential therapeutic targets.
|
30423295 |
2018 |
|
Pervasive Development Disorder
|
0.010 |
GeneticVariation
|
group |
BEFREE |
A study of single nucleotide polymorphisms in CD157, AIM2 and JARID2 genes in Han Chinese children with autism spectrum disorder.
|
29216786 |
2018 |
|
Chronic myeloproliferative disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic deletion of Jarid2 either reduced overall survival of animals with MPNs or drove transformation to sAML, depending on the timing and context of co-operating mutations.
|
30423295 |
2018 |
|
MYELODYSPLASTIC SYNDROME
|
0.010 |
Biomarker
|
group |
BEFREE |
JARID2 is lost by chromosomal deletions in a proportion of MPN/MDS cases that progress to sAML.
|
30423295 |
2018 |
|
Cleft Palate
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Four SNPs in CRISPLD2 (rs1546124, rs8061351, rs2326398, and rs4783099) and four in JARID2 (rs915344, rs2299043, rs2237138, and rs2076056), that were previously reported to be associated with NSCL/P, were genotyped in 785 Brazilian patients with NSCL/P (549 with cleft lip with or without cleft palate-NSCL ± P, and 236 with cleft palate only-NSCPO) and 693 unaffected Brazilian controls.
|
27328068 |
2017 |
|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
MiR-155 contributes to Th17 cells differentiation in dextran sulfate sodium (DSS)-induced colitis mice via Jarid2.
|
28461115 |
2017 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, JARID2 may serve as a potential therapeutic target for the treatment of glioma.
|
27641964 |
2017 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The expression of MEG3 long noncoding RNA (lncRNA), which could interact with JARID2, was clearly increased during transforming growth factor-β (TGF-β)-induced EMT of human lung cancer cell lines.
|
27852821 |
2017 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The expression of MEG3 long noncoding RNA (lncRNA), which could interact with JARID2, was clearly increased during transforming growth factor-β (TGF-β)-induced EMT of human lung cancer cell lines.
|
27852821 |
2017 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, JARID2 may represent a potential therapeutic target for the treatment of ovarian cancer.
|
28765957 |
2017 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, JARID2 may represent a potential therapeutic target for the treatment of ovarian cancer.
|
28765957 |
2017 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The expression of MEG3 long noncoding RNA (lncRNA), which could interact with JARID2, was clearly increased during transforming growth factor-β (TGF-β)-induced EMT of human lung cancer cell lines.
|
27852821 |
2017 |
|
Cleft palate, isolated
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Four SNPs in CRISPLD2 (rs1546124, rs8061351, rs2326398, and rs4783099) and four in JARID2 (rs915344, rs2299043, rs2237138, and rs2076056), that were previously reported to be associated with NSCL/P, were genotyped in 785 Brazilian patients with NSCL/P (549 with cleft lip with or without cleft palate-NSCL ± P, and 236 with cleft palate only-NSCPO) and 693 unaffected Brazilian controls.
|
27328068 |
2017 |
|
Uranostaphyloschisis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Four SNPs in CRISPLD2 (rs1546124, rs8061351, rs2326398, and rs4783099) and four in JARID2 (rs915344, rs2299043, rs2237138, and rs2076056), that were previously reported to be associated with NSCL/P, were genotyped in 785 Brazilian patients with NSCL/P (549 with cleft lip with or without cleft palate-NSCL ± P, and 236 with cleft palate only-NSCPO) and 693 unaffected Brazilian controls.
|
27328068 |
2017 |
|
Oral cleft
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Haplotype analysis indicated a lack of association between JARID2 haplotypes and non-syndromic oral cleft risk.
|
27328068 |
2017 |
|
Abnormality of cardiovascular system morphology
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Within our clinical cohort, we also observed heterozygous LOF variants in JARID2 and SMAD1 in individuals with cardiac phenotypes, and collectively, carriers of LOF variants in our candidate genes had a four times higher odds of having CVM (odds ratio = 4.0, 95% confidence interval 2.5-6.5).
|
29089047 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, JARID2 may represent a potential therapeutic target for the treatment of ovarian cancer.
|
28765957 |
2017 |
|
leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that JARID2 is a negative regulator of leukemia cell proliferation, and functions as potential tumor suppressor in leukemia.
|
25939703 |
2015 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
JARID2 is down-regulated in B-chronic lymphocytic leukemia (B-CLL) and acute monocytic leukemia (AMOL), and knockdown of JARID2 promotes leukemia cell proliferation via acceleration of the G1/S transition.
|
25939703 |
2015 |